NeoStem, Inc., a biopharmaceutical company, engages in the development and manufacture of cellular therapies for oncology, immunology and regenerative medicine. It provides adult stem cell collection, processing, and storage services that enable healthy individuals to donate and store their stem cells for personal therapeutic use. Further, the company provides AMR-001, a chemotactic hematopoietic stem cell product that has completed Phase 1 trial for the treatment of damaged heart muscle, as well as involved in developing a T-cell therapy for a range of autoimmune conditions. The Company pursues the divestiture of its Pharmaceutical Manufacturing segment in China and anticipate it will have been exited by the close of 2012.

Acquired Companies: Amorcyte, Inc., PCT Cell Therapy Services, Suzhou Erye Pharmaceutical